Quick Answer
HeartSciences Inc. reported Operating Income Loss of -$8.35 million for the year ending 2025.
- HeartSciences Inc. showed a decrease of -32.5% in Operating Income Loss from 2024 to 2025.
- This data is from HeartSciences Inc.'s annual report (Form 10-K), filed with the SEC on July 24, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$674.4 thousand | Q4 2021: -$956.9 thousand | Q1 2022: -$1.10 million | Q3 2022: -$1.43 million | Q4 2022: -$1.77 million | Q1 2023: -$1.31 million | Q3 2023: -$1.33 million | Q4 2023: -$1.57 million | Q1 2024: -$1.53 million | Q3 2024: -$2.08 million | Q4 2024: -$1.99 million | Q1 2025: -$2.37 million | Q3 2025: -$1.87 million | Q4 2025: -$2.07 million | Q1 2026: -$1.93 million.
- Over the full 4 years of available data (2022 to 2025), HeartSciences Inc.'s Operating Income Loss has declined by 77.4%.
- Historical annual values: Fiscal year 2025: -$8.35 million | Fiscal year 2024: -$6.31 million | Fiscal year 2023: -$6.11 million | Fiscal year 2022: -$4.71 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: